Copyright © 1994 by the European Society of Cardiology.
© 1994 The European Society of Cardiology
Chronic oral pretreatment with the angiotensin converting enzyme inhibitor, trandolapril decreases ventricular fibrillation in acute ischaemia and reperfusion
MRC Ischaemic Heart Disease Research Unit, Department of Medicine, Groote Schuur Hospital and University of Cape Town Faure, South Africa
*National Accelerator Centre Faure, South Africa
Received 6 July 1993; revised 24 February 1994; .
Correspondence: Dr C. A. Muller, Heart Research Unit, Medical School, University of Cape Town, Observatory 7925, Cape Town, South Africa.
Abstract
The effect of chronic angiotensin converting enzyme (ACE) inhibition on the incidence of fatal ventricular fibrillation during regional myocardial ischaemia and reperfusion is not known. A reduction in cardiac angiotensin II and/or a vagomimetic response may result in antiarrhythmic activity. Pigs pre-treated with the ACE inhibitor trandolapril 0.3 mg. kg–1 or placebo orally for 10 days were subjected to thoracotomy. The left anterior descending coronary artery was ligated (CAL) for 20 min and reperfused for 45 min. Trandolapril decreased cardiac ACE activity and prevented the fall in the ventricular fibrillation threshold (VFT) during ischaemia: after 5 min of ischaemia the VET in the trandolapril group was 25.5 ± 4.6 mA (mean ± SEM) vs 13.1 ± 2.2 mA in the placebo group (P<0.05). Trandolapril also decreased the incidence of spontaneous ventricular fibrillation during reperfusion to 116 vs 617 in the placebo group (P<0.05). Heart rate in the trandolapril group fell. During ischaemia, trandolapril increased blood flow in the non-ischaemic zone, but decreased blood flow in the central ischaemic zone of the left ventricle. Similarly it decreased tissue levels of phosphocreatine in this zone. During reperfusion trandolapril increased blood flow both in non-ischaemic and central ischaemic zones. Chronic oral pre-treatment with trandolapril resulted in marked antifibrillatory effects which were associated with inhibition of cardiac ACE activity and a decreased heart rate.
Key Words: ACE inhibition • arrhythmias • myocardial blood flow
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E du Toit, D Hofmann, J McCarthy, and C Pineda Effect of levosimendan on myocardial contractility, coronary and peripheral blood flow, and arrhythmias during coronary artery ligation and reperfusion in the in vivo pig model Heart, July 1, 2001; 86(1): 81 - 87. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Khalil, A. W. Basher, E. J. Brown Jr, and I. A. Alhaddad A remarkable medical story: benefits of angiotensin-converting enzyme inhibitors in cardiac patients J. Am. Coll. Cardiol., June 1, 2001; 37(7): 1757 - 1764. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Muller, L. H. Opie, J. McCarthy, D. Hofmann, C. A. Pineda, and M. Peisach Effects of mibefradil, a novel calcium channel blocking agent with T-type activity, in acute experimental myocardial ischemia: maintenance of ventricular fibrillation threshold without inotropic compromise J. Am. Coll. Cardiol., July 1, 1998; 32(1): 268 - 274. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Kupatt, H. Habazettl, S. Zahler, C. Weber, B. F Becker, K. Messmer, and E. Gerlach ACE-inhibition prevents postischemic coronary leukocyte adhesion and leukocyte-dependent reperfusion injury Cardiovasc Res, December 1, 1997; 36(3): 386 - 395. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Kober, C. Torp-Pedersen, J. E. Carlsen, H. Bagger, P. Eliasen, K. Lyngborg, J. Videbak, D. S. Cole, L. Auclert, N. C. Pauly, et al. A Clinical Trial of the Angiotensin-Converting-Enzyme Inhibitor Trandolapril in Patients with Left Ventricular Dysfunction after Myocardial Infarction N. Engl. J. Med., December 21, 1995; 333(25): 1670 - 1676. [Abstract] [Full Text] [PDF]
|
|